Cargando…
Noninvasive imaging signatures of HER2 and HR using ADC in invasive breast cancer: repeatability, reproducibility, and association with pathological complete response to neoadjuvant chemotherapy
BACKGROUND: The immunohistochemical test (IHC) of HER2 and HR can provide prognostic information and treatment guidance for invasive breast cancer patients. We aimed to develop noninvasive image signatures IS(HER2) and IS(HR) of HER2 and HR, respectively. We independently evaluate their repeatabilit...
Autores principales: | Teng, Xinzhi, Zhang, Jiang, Zhang, Xinyu, Fan, Xinyu, Zhou, Ta, Huang, Yu-hua, Wang, Lu, Lee, Elaine Yuen Phin, Yang, Ruijie, Cai, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308682/ https://www.ncbi.nlm.nih.gov/pubmed/37381020 http://dx.doi.org/10.1186/s13058-023-01674-9 |
Ejemplares similares
-
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021) -
Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial
por: Newitt, David C., et al.
Publicado: (2020) -
Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021) -
Repeatability and Reproducibility of Noninvasive Keratograph 5M Measurements in Patients with Dry Eye Disease
por: Tian, Lei, et al.
Publicado: (2016) -
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2(+)/HR(−) Trial
por: Graeser, Monika, et al.
Publicado: (2023)